Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing …

LR Minces, MH Nguyen, D Mitsani… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Ganciclovir-resistant cytomegalovirus (CMV) infections are reported infrequently among
lung transplant recipients receiving extended valganciclovir prophylaxis. We performed a …

A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome

AJ Reddy, AK Zaas, KE Hanson, SM Palmer - The Journal of heart and lung …, 2007 - Elsevier
BACKGROUND: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality
after lung transplantation despite ganciclovir prophylaxis. The emergence of ganciclovir …

The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation

RM Kruger, WD Shannon, MQ Arens, JP Lynch… - …, 1999 - journals.lww.com
Background. Cytomegalovirus (CMV) resistance to ganciclovir has become increasingly
common in acquired immu; nodeficiency syndrome patients but has only rarely been …

Clinical impact of ganciclovir‐resistant cytomegalovirus infections in solid organ transplant patients

G Boivin, N Goyette, C Gilbert, A Humar… - Transplant infectious …, 2005 - Wiley Online Library
Clinical consequences of ganciclovir resistant cytomegalovirus (CMV) infections were
studied during 2 large prophylactic trials consisting of 100 days of valganciclovir or …

Subtherapeutic ganciclovir (GCV) levels and GCV‐resistant cytomegalovirus in lung transplant recipients

JP Gagermeier, JD Rusinak, NS Lurain… - Transplant Infectious …, 2014 - Wiley Online Library
Background Cytomegalovirus (CMV) infection results in significant morbidity and mortality in
lung transplant recipients. Ganciclovir (GCV) has dramatically reduced complications …

Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients

SM Bhorade, NS Lurain, A Jordan, J Leischner… - The Journal of heart and …, 2002 - Elsevier
BACKGROUND: Since ganciclovir-resistant cytomegalovirus (CMV) disease was initially
described in a patient with acquired immunodeficiency syndrome (AIDS) in 1986, the …

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis

D Mitsani, MH Nguyen, EJ Kwak, FP Silveira… - The Journal of Heart and …, 2010 - Elsevier
BACKGROUND: Valganciclovir prophylaxis is advocated for lung transplant recipients, but
its efficacy is unknown. METHODS: Retrospective review was done of 109 donor …

Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation

VG Valentine, D Weill, MR Gupta, B Raper… - The Journal of heart and …, 2008 - Elsevier
BACKGROUND: Universal ganciclovir (GCV) prophylaxis is a strategy aimed at reducing
cytomegalovirus (CMV) infection and delaying the development of bronchiolitis obliterans …

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

AP Limaye, G Raghu, DM Koelle… - The Journal of …, 2002 - academic.oup.com
Preemptive antiviral therapy in transplant patients is thought to be less likely to lead to
antiviral resistance than is routine prophylaxis. Cytomegalovirus (CMV)–seropositive lung …

[HTML][HTML] Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection

L Cherrier, A Nasar, KJ Goodlet, MD Nailor… - American Journal of …, 2018 - Elsevier
Following a year of valganciclovir prophylaxis, a lung transplant recipient developed
cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by …